Table 6.

Comparison of incidence of antidrug antibodies (anti-risankizumab antibodies) and neutralizing antibodies to risankizumab over up to 52 weeks’ duration in Japanese and non-Japanese subjects with moderate-to-severe plaque psoriasis, GPP, EP, or psoriatic arthritis in global phase III or Japanese phase II/III studies

Population	Japanese subjects who received at least one dose of risankizumab 75–150 mg SC		Non-Japanese subjects who received at least one dose of risankizumab 75–150 mg SC
	Plaque psoriasis, GPP, or EP	Psoriatic arthritis	Plaque psoriasis	Psoriatic arthritis
Evaluable subjects (n)	228	11	1322	129
ADA incidence (treatment-emergent) [n (%)]	54 (23.7)	1 (9.1)	296 (22.4)	16 (12.4)
NAb incidence (treatment-emergent) [n (%)]	23 (10.9)a	0 (0)	177 (13.4)	0 (0)

Evaluable subjects: subjects with at least one reportable assessment at any time in the study post-baseline

NAb were assessed only when the ADA assessment was confirmed positive

ADA antidrug antibody (anti-risankizumab antibody), NAb neutralizing antibody, SC subcutaneously, GPP generalized pustular psoriasis, EP erythrodermic psoriasis

^aBased on 211 evaluable Japanese subjects as NAb was not assessed in Study 10